A5031681242- Neuroinflammation and Neurodegeneration Mechanisms
- Inflammation biomarkers and pathways
- Parkinson's Disease Mechanisms and Treatments
- Conducting polymers and applications
- Alzheimer's disease research and treatments
Stanford University
2019-2024
Parkinson's disease is the second most common neurodegenerative after Alzheimer's and affects 1% of population above 60 years old. Although commonly manifests with motor symptoms, a majority patients subsequently develop cognitive impairment, which often progresses to dementia, major cause morbidity disability. characterized by α-synuclein accumulation that frequently associates amyloid-β tau fibrils, hallmarks neuropathological changes; this co-occurrence suggests onset decline in may be...
SUMMARY Human genetics implicate defective myeloid responses in the development of late onset, age-associated Alzheimer’s disease (AD). Aging is characterized by a decline metabolism that triggers maladaptive, neurotoxic immune responses. TREM1 an amplifier pro-inflammatory responses, and here we find Trem1 deficiency prevents age-dependent changes metabolism, inflammation, hippocampal memory function. rescues declines ribose-5P, glycolytic intermediate precursor for purine, pyrimidine, NAD...
Abstract Parkinson’s disease (PD) is the second most common neurodegenerative after Alzheimer’s (AD) and affects 1% of population above 60 years old. Although PD commonly manifests with motor symptoms, a majority patients subsequently develop cognitive impairment which often progresses to dementia, major cause morbidity disability. characterized by α-synuclein accumulation that frequently associates amyloid beta (Aβ) tau fibrils, hallmarks AD neuropathologic changes; this co-occurrence...